Liver Cancer Lab

Good morning Barcelona! Looking forward to day second of #WCGIC2022 Starting off with challenging #HCC cases with @DucreuxMichel @GABOUALFA Bruno Sangro Rene Adams and Thierry de Baere

New #immunotherapy kids on the block for advanced #CRC? Very promising data presented #WCGCI2022 Botensilimab and Balstilimab —> Fc enhanced CTLA4/PD1 combination Compelling ORR of 24% Is there a role of liver mets for IO efficacy? @myESMO @OncoAlert

Looking forward to a great symposium on #PrecisionMedicine in #cholangiocarcinoma 👉join us 13:00 at #WCGIC2022 to discuss targeted therapies with #JohnBridgewater #EricvanCutsem @LorenzaRimassa @myESMO @enscca

Super proud of my colleague @ArndtVogel for presenting the final analysis of the practice changing Fight-202 trial for pts with FGFR2 altered #cholangiocarcinoma at #WCGIC2022 #livertwitter

⭐️#BRAF #TissueAgnostic #PrecisionMedicine @OncoAlert

👏Comprehensive review on BRAF V600E doi: 10.1158/1535-7163.MCT-21-0950 👉detected in > 40 cancer types 👉BRAF inhibition effective > 20 cancer types 👉RWD in 69 cancer types 👉BRAFi/MEKi > BRAFi , but CRC + EGFRi 👉9 FDA approvals, now tumor-agnostic @OncoAlert @myESMO

👏Understanding evolution of resistance to targeted therapy doi.org/10.1038/s41587…. ❓selection or de novo acquisition? 👉CaTCH: method to analyze founder clones their postselection counterparts Proof of concept for RAFi/MEKi resistance #precisionmedicine

#WCGIC2022 #Youngoncologist sessions: 'ESMO Session: Focus on Young Oncologists, with #ESMOYOC', plus finding local & intl. mentors to build your career, #Gendermedicine in #GItumours, disparities in access to new drugs 👇 🔗 ow.ly/SEoF50JIiES @ESMOWorldGI #GIcancer

💊💊Critical appraisal of FDA approvals: food for thoughts! doi.org/10.1038/s41571… 👉 71 2002-14 👉161 2017-21 👉71 IO 💉 👉 62 small molecules💊 👉 5 T-agnostic ✅ 47 with OS ❗️ 58 with ORR ❗️ 39 with PFS ❗️only 42 with subs. benefit acc.ESMO-MCBS @myESMO #Immunotherapy

Great day to start ESMO-Gi in Barcelona

Watch on demand: today's tumor heterogeneity symposium #ILC2022 with @Valeriechew29 from 🇸🇬: ⬆️immune intratumoral heterogeneity is associated with ⬆️immunosuppressive tumor microenvironment and ⬇️clinical outcome parameters in #HCC 👉nature.com/articles/s4146… #LiverTwitter

EASL YI task force preparing for the YI Seminar tomorrow at 08:00 sharp😀. Make sure to join us there, early birds 🦆 @EASLedu #LiverTwitter #ILC2022

Hurry up or you will miss Heiner Wedemeyer‘s Talk in the YI Symposium ! Capital Suite 17! Now! No excuses! #ILC2022

Entertaining and informative talk by H. Wedemeyer ➡️history of discoveries of hepatitis viruses ➡️landmark publications and their ➡️impact on hepatitis treatment strategies A grand start to the YI Symposium ⭐️(And I am NOT saying this bc he is my boss…)

This is EXACTLY what we aimed for when preparing the yi symposium: excellent speakers that take us on a journey 🧭through their field, highlighting novel developments but also dead ends. Thank you @analleo for your insights and advice!#ILC2022 #LiverTwitter

Future of metabol. liver disease research: key insights from M. Vacca: ❗️Stop using 2D cultures for metabolic studies, go for precision cut liver slices ❗️multi organ on chip and ❗️advanced natural ecm organoids is what we should aim for ‼️Consensus on preclin. models are key!

🔥FGFR2 alterations in #cholangiocarcinoma 👉fusion: FGFR2 intron 17/exon 18 breakpoint; partner is known or novel/in-frame with FGFR2 👉rearrangement: gene is out-of-frame with ex. 17 👉truncation: loss of neg. regulatory element 👉In-Frame Deletion.. ✅all druggable @myESMO

🔥concerning data on acetaminophen for #immunotherapy @JCO_ASCO doi.org/10.1016/j.anno… 👉APAP --> Treg⬆️ --> IO efficacy⬇️: ORR, PFS, OS ❗️be aware of concomitant💊💊:statins, steroids, antibiotics, proton-pump inhibitors... @OncoAlert @myESMO

👏Excellent summary on Hyperprogression and #Immunotherapy in @trendscancer doi.org/10.1016/j.trec… 👉no clear definition, only retros. data 👉no biomarker ❓role of TME ✅clear need to identify patients with devastating outcome on ICI @OncoAlert, @myESMO

YI Paula Olaizola presenting her comprehensive work on the role of NEDDylation in #cholangiocarcinoma in the abstract session ➡️targeting NEDDylation pharmacologically or genetically impacts tumor growth in vitro & in vivo 👏to new takes on CCA! #LiverTwitter #ILC2022